THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma
- 1 September 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 171 (3), R111-R122
- https://doi.org/10.1530/eje-14-0113
Abstract
Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicians with three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centers with multidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.Keywords
This publication has 55 references indexed in Scilit:
- Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic IndicatorsJournal of Clinical Endocrinology & Metabolism, 2011
- Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytomaEndocrine-Related Cancer, 2008
- Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or ParagangliomasJournal of Clinical Endocrinology & Metabolism, 2007
- Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and ParagangliomaJournal of Clinical Oncology, 2007
- Gastroenteropancreatic endocrine tumors: clinical characterization before therapyNature Clinical Practice Endocrinology & Metabolism, 2007
- Genetic Testing in Pheochromocytoma or Functional ParagangliomaJournal of Clinical Oncology, 2005
- Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free MetanephrinesClinical Chemistry, 2005
- The value of plasma markers for the clinical behaviour of phaeochromocytomasActa Endocrinologica, 2002
- Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol-O-Methyltransferase Within TumorsJournal of Clinical Endocrinology & Metabolism, 1998
- Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein HormonesJournal of Clinical Endocrinology & Metabolism, 1997